Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 5/20 | 0.55 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.52 |
| ▸ | DRD2 | P14416 | 6/20 | 0.51 |
| ▸ | DRD4 | P21917 | 6/20 | 0.51 |
| ▸ | DRD3 | P35462 | 6/20 | 0.51 |
| ▸ | ACHE | P22303 | 2/20 | 0.48 |
| ▸ | CCR3 | P51677 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3262861 | 0.83 | CHRM3 (0.54) | CHRM3OPRL1OPRM1OPRK1CHRM2 | |
| SCHEMBL13801356 | 0.80 | LMNA (0.45) | CHRM3OPRL1OPRM1OPRK1 | |
| SCHEMBL2212740 | 0.78 | LMNA (0.43) | — | |
| SCHEMBL3075361 | 0.77 | OPRL1 (0.66) | CHRM3OPRL1OPRM1OPRK1CHRM2 | |
| SCHEMBL3959455 | 0.77 | LMNA (0.47) | — | |
| SCHEMBL14410222 | 0.77 | LMNA (0.46) | OPRL1OPRM1OPRK1 | |
| SCHEMBL250673 | 0.76 | ACHE (0.69) | CHRM3OPRL1OPRM1OPRK1DRD2 | |
| Hydrochloric Acid SCHEMBL2208949 | 0.76 | LMNA (0.46) | — | |
| SCHEMBL3073412 | 0.75 | OPRL1 (0.60) | CHRM3OPRL1OPRM1OPRK1CHRM2 | |
| SCHEMBL13945986 | 0.75 | CHRM3 (0.60) | CHRM3OPRL1OPRM1OPRK1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-7498325-B2 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | KARL THOMAS GMBH (DE) | 2009-03-03 | — | — | US | disclosed |
| EP-1440976-B1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-07-23 | — | — | EP | disclosed |
| US-20040214819-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2004-10-28 | — | — | US | disclosed |
| EP-1440976-A1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-07-28 | — | — | EP | disclosed |
| EP-0927192-B1 | MODIFIED AMINOACIDS, PHARMACEUTICALS CONTAINING THESE COMPOUNDS AND METHOD FOR THEIR PRODUCTION | BOEHRINGER INGELHEIM PHARMA (DE) | 2004-05-12 | — | — | EP | disclosed |
| US-20030069231-A1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | RUDOLF KLAUS (DE) | 2003-04-10 | — | — | US | disclosed |
| US-6344449-B1 | HEADACHE AND MORPHINE DEPENDENCE | DR. KARL THOMAE GMBH (DE) | 2002-02-05 | — | — | US | disclosed |
| US-20010036946-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | RUDOLF KLAUS (DE) | 2001-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, CHRM1, SRMS | CHRM3 30/4885OPRL1 73/4885OPRM1 10/4885 |
| US-20040214819-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, SRMS, OPRM1 | CHRM3 49/4885OPRL1 71/4885OPRM1 3/4885 |
| US-20030069231-A1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | SLC1A5, NEFM, SRMS | CHRM3 46/4885OPRL1 116/4885OPRM1 6/4885 |
| US-20010036946-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, SRMS, OPRM1 | CHRM3 49/4885OPRL1 71/4885OPRM1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.